Replies to post #160870 on Biotech Values

[ariadndndough]

Zipjet
Citi agrees with you

Iclusig Estimates — We are increasing our 2013 WW Iclusig sales estimates to $81M (+$26M), reflecting the stronger than anticipated early US uptake and the recognition of deferred French Iclusig sales during 2H

We believe Ariad’s ponatinib is “best in class” in the ~$5bn WW CML market and expect above consensus ponatinib sales after 2014 and for its lung cancer drug AP26113 sales beginning in 2015. In our view, the breadth of ponatinib’s opportunities in both the resistant/intolerant and front-line CML settings continues not to be reflected in Ariad’s valuation. In addition, we believe the Street underestimates the potential commercial opportunities for an agent with `113’s profile. We expect aggressive development for the program will increase awareness of the breath and size of addressable populations and subsequent consideration to ARIA’s valuation.